Canada's Aurinia Pharma Q4 revenue jumps on LUPKYNIS demand

Aurinia Pharmaceuticals

26/02/2026 11:15

Overview

Canada biopharma's Q4 revenue grew 29% yr/yr

Net income for Q4 surged due to income tax benefit

Company repurchased 12.2 mln shares for $98.2 mln

Outlook

Aurinia expects 2026 total revenue between $315 mln and $325 mln

Company projects 2026 LUPKYNIS sales of $305 mln to $315 mln

Aurinia plans clinical studies for aritinercept in autoimmune diseases in early 2026

Result Drivers

LUPKYNIS SALES GROWTH - Net product sales of LUPKYNIS increased 29% in Q4 and 25% for the year, driving revenue growth

INCOME TAX BENEFIT - Net income surged due to a $175.1 mln income tax benefit from the release of valuation allowance on deferred tax assets

ROYALTY REVENUE DECLINE - License, collaboration, and royalty revenue decreased 38% for the year due to absence of prior year's milestone payment

Company press release: ID:nBw7fnM1ma

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$74.17 mln
Q4 Net Income
$210.79 mln
Q4 Operating Expenses
$43.88 mln
Q4 Operating Income
$33.24 mln
Q4 Pretax Profit
$35.69 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $17.00, about 17.8% above its February 25 closing price of $14.43

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)